AAAAAA

   
Results: 1-7 |
Results: 7
SUCCESSFUL FETAL-OUTCOME AFTER EXPOSURE TO IDARUBICIN AND CYTOSINE-ARABINOSIDE DURING THE 2ND-TRIMESTER OF PREGNANCY - A CASE-REPORT
Authors: CLAAHSEN HL SEMMEKROT BA VANDONGEN PWJ MATTIJSSEN V
Citation: Hl. Claahsen et al., SUCCESSFUL FETAL-OUTCOME AFTER EXPOSURE TO IDARUBICIN AND CYTOSINE-ARABINOSIDE DURING THE 2ND-TRIMESTER OF PREGNANCY - A CASE-REPORT, American journal of perinatology, 15(5), 1998, pp. 295-297
OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH LYMPHOCYTE-DEPLETED MARROW GRAFTS IN ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES
Authors: MATTIJSSEN V SCHATTENBERG A SCHAAP N PREIJERS F DEWITTE T
Citation: V. Mattijssen et al., OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH LYMPHOCYTE-DEPLETED MARROW GRAFTS IN ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES, Bone marrow transplantation, 19(8), 1997, pp. 791-794
THE PROGNOSTIC IMPACT OF THE PRESENCE OF AN HLA-IDENTICAL DONOR ON PATIENTS WITH HIGH-RISK MDS AND AML FOLLOWING MDS TREATED WITH AN INTENSIVE ANTILEUKEMIC REGIMEN
Authors: MATTIJSSEN V",DEWITTE,"SUCIU S BOOGAERTS M LABAR B ARCHIMBAUD E AUL C SELLESLAG D FERRANT A WEIJERMANS P MANDELLI F AMADORI S JEHN U MUUS P DEMUYNCK H DARDENNE M WILLEMZE R GRATWOHL A APPERLEY J
Citation: S. Mattijssen V",dewitte,"suciu et al., THE PROGNOSTIC IMPACT OF THE PRESENCE OF AN HLA-IDENTICAL DONOR ON PATIENTS WITH HIGH-RISK MDS AND AML FOLLOWING MDS TREATED WITH AN INTENSIVE ANTILEUKEMIC REGIMEN, Blood, 88(10), 1996, pp. 1908-1908
DOCETAXEL (TAXOTERE(R)) - AN ACTIVE-DRUG FOR THE TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
Authors: CATIMEL G VERWEIJ J MATTIJSSEN V HANAUSKE A PICCART M WANDERS J FRANKLIN H LEBAIL N CLAVEL M KAYE SB
Citation: G. Catimel et al., DOCETAXEL (TAXOTERE(R)) - AN ACTIVE-DRUG FOR THE TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK, Annals of oncology, 5(6), 1994, pp. 533-537
INTRATUMORAL PEG-INTERLEUKIN-2 THERAPY IN PATIENTS WITH LOCOREGIONALLY RECURRENT HEAD AND NECK SQUAMOUS-CELL CARCINOMA
Authors: MATTIJSSEN V DEMULDER PH DEGRAEFF A HUPPERETS PS JOOSTEN F RUITER DJ BIER H PALMER PA VANDENBROEK P
Citation: V. Mattijssen et al., INTRATUMORAL PEG-INTERLEUKIN-2 THERAPY IN PATIENTS WITH LOCOREGIONALLY RECURRENT HEAD AND NECK SQUAMOUS-CELL CARCINOMA, Annals of oncology, 5(10), 1994, pp. 957-960
LOCOREGIONAL THERAPY WITH POLYETHYLENE-GLYCOL-MODIFIED INTERLEUKIN-2 OF AN INTRADERMALLY GROWING HEPATOCELLULAR-CARCINOMA IN THE GUINEA-PIGINDUCES T-CELL-MEDIATED ANTITUMOR-ACTIVITY
Authors: BALEMANS LTM MATTIJSSEN V STEERENBERG PA VANDRIEL BEM DEMULDER PHM DENOTTER W
Citation: Ltm. Balemans et al., LOCOREGIONAL THERAPY WITH POLYETHYLENE-GLYCOL-MODIFIED INTERLEUKIN-2 OF AN INTRADERMALLY GROWING HEPATOCELLULAR-CARCINOMA IN THE GUINEA-PIGINDUCES T-CELL-MEDIATED ANTITUMOR-ACTIVITY, Cancer immunology and immunotherapy, 37(1), 1993, pp. 7-14
E-CADHERIN EXPRESSION IN HEAD AND NECK SQUAMOUS-CELL CARCINOMA IS ASSOCIATED WITH CLINICAL OUTCOME
Authors: MATTIJSSEN V PETERS HM SCHALKWIJK L MANNI JJ VANTHOFGROOTENBOER B DEMULDER PHM RUITER DJ
Citation: V. Mattijssen et al., E-CADHERIN EXPRESSION IN HEAD AND NECK SQUAMOUS-CELL CARCINOMA IS ASSOCIATED WITH CLINICAL OUTCOME, International journal of cancer, 55(4), 1993, pp. 580-585
Risultati: 1-7 |